BMC Hematology | Full text

BMC Hematology | Full text

BMC Hematology | Full text
Posttransplantation human herpesvirus-8 (HHV8)/Kaposi sarcoma herpesvirus (KSHV) primary infection and/or reactivations are associated with uncommon and sometimes fatal, neoplastic, and non-neoplastic diseases. In the context of human immunodeficiency virus (HIV) infection, MCD is associated with human herpesvirus 8 (HHV8) infection. A healthy immune system involves a complex and interconnected network of cells and inflammatory messengers (cytokines), which signal for the immune system to activate. But a July 2008 letter to the editor that appeared in Nature suggested that that may not always be the case and that one day there may be a herpes cure. SYLVANT is an IL-6 antagonist biologic therapy administered as an intravenous (IV) infusion once every three weeks.[1] SYLVANT is the first approved treatment in the U.S. Demographic, clinical features and treatment results were reviewed retrospectively in all patients. Note: In calculating the moving wall, the current year is not counted.

Prolonged compromise of immune function, through conditions such as HIV/AIDS or through IMMUNOSUPPRESSIVE THERAPY such as occurs following ORGAN TRANSPLANTATION, allows HHV-8 to replicate (reproduce itself by taking over healthy cells) and cause Kaposi’s sarcoma. Therapy directed at the IL-6 receptor4,5 as well as monoclonal antibodies directed against IL-6 itself have shown clinical activity5-7 in MCD. After history-taking and a medical examination, medical imaging scans will help to inform a diagnosis, which can be confirmed definitively through laboratory analysis of a tumor sample. The pleural effusion completely resolved following six cycles of R-CHOP therapy, and the patient remained in continuous, complete remission for the next nine years, eventually dying from complications of late-onset diabetes with no evidence of recurrent lymphoma. De Jong RB, Kluin PM, Rosati S, Van Haelst PL, Sprenger HG, Van Spronsen DJ: Sustained high levels of serum HHV-8 DNA years before multicentric Castleman’s disease despite full suppression of HIV with highly active antiretroviral therapy. Additionally, there are rare reports of some of EBV and HHV-8 positive LPDs occurring in the absence of immunodeficiency 10,17. The etiology of UCD is poorly understood, and there is usually no excess interleukin-6 (IL-6) secretion.

You may also like